35 results about "Clostridium organisms" patented technology

The application relates to the field of biotechnology, in particular to a Faecalibacterium prausnitzii microbial anti-inflammatory molecule and a screening method and application thereof. The amino acid sequence of the Faecalibacterium prausnitzii microbial anti-inflammatory molecule is shown in (a) or (b); (a) the amino acid sequence is shown in SEQ ID NO. 1; (b) a protein derived from (a) with anti-inflammatory activity obtained by substituting, deleting or adding one or more amino acids in the amino acid sequence in (a). Compared with the microbial anti-inflammatory molecule protein of a representative strain A2-165 of the Faecalibacterium genus, the inhibiting effects of the Faecalibacterium prausnitzii microbial anti-inflammatory molecule on the NF-kappa B signal pathway and the inflammatory factor TNF alpha are 50% and 56% respectively, and the anti-inflammatory effect (inhibiting the NF-kappa B signal pathway) of the Faecalibacterium prausnitzii microbial anti-inflammatory molecule screened in the application can reach more than 90%, and the Faecalibacterium prausnitzii microbial anti-inflammatory molecule has the advantages of small use dosage and strong anti-inflammatory effect.

The invention belongs to the technical field of biology, and particularly relates to a Sardinia clostridium 7alpha-hydroxysteroid dehydrogenase mutant S161G. The amino acid sequence of the mutant S161G is as shown in SEQ ID NO: 2, and the amino acid sequence of the mutant S161G is obtained by mutating Ser at the 161st site of a wild type sequence SEQ ID NO: 1 into Gly. The catalytic efficiency of the mutant S161G on substrates NADP < + > and TCDCA is 3.82 times that of a wild type. The mutant S161G provided by the invention has huge application potential in the industrial production process of obtaining TUDCA or UDCA through biotransformation.

Form-specific cell based assays for the characterization of Clostridia botulinum neurotoxins and genetically modified cells utilized in such assays are described. Such assays and genetically modified cells can discriminate between complexed and non-complexed forms of botulinum neurotoxin having the same serotype, for example serotype E. Methods are also provided for generating and identifying cell lines that can be utilized in such cell based assays.

A piezoelectric plate sensor comprising a piezoelectric layer; two electrodes; and an insulation layer. The insulation layer is produced by soaking the piezoelectric layer and two electrodes in a mercaptopropyltrimethoxysilane solution with an amount of water from 0.1 v / v. % to about 1 v / v % and at pH from about 8 to about 150 for a period from about 8 to about 15 hours, and the mercaptopropyltrimethoxysilane solution has a concentration of mercaptopropyltrimethoxysilane from about 0.01 v / v % to about 0.5 v / v %. A method of detecting a biomolecule in a sample using the piezoelectric plate sensor in particular, that of detecting a genetic marker with PCR sensitivity and specificity without the need of DNA isolation or amplification is also provided. The piezoelectric plate sensor may be used to diagnose various diseases including breast cancer, myocardial infarction, diarrhea, Clostridium difficile infection, and hepatitis B infection.

This invention belongs to the field of biotechnology and discloses a monoclonal antibody that specifically binds to the recombinant protein of Clostridium perfringens (Cp) β2 toxin, a hybridoma cell line, and its applications. This invention provides a monoclonal antibody that specifically binds to the β2 toxin protein and a hybridoma cell line CPB2-2A4 (accession number CCTCC NO: C2024312) that secretes this monoclonal antibody. The monoclonal antibody reacts only with the Cp β2 toxin protein and does not cross-react with other pathogens infecting cattle and sheep, exhibiting extremely high specificity. The kit utilizes competitive ELISA technology, using a mouse monoclonal antibody that specifically binds to the Cp β2 toxin recombinant protein as a competing antibody, enabling the detection of Cp β2 toxin antibodies in serum from various animal sources, avoiding species limitations of sample sources. Furthermore, the kit exhibits good reproducibility. The kit has relatively relaxed technical requirements during operation and can be widely used in production for applications such as Cp epidemiological surveys and vaccine immunization level monitoring.

This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and / or toxin B.

The application provides a bacteriostatic and deodorizing composite preparation for pets and application thereof, which comprises 30-40% of enzyme preparation, 20-30% of plant extract, 20-30% of probiotic powder, and 0-10% of inorganic salt and filling aid. The application can efficiently remove ammonia and effectively reduce the ammonia gas yield in excrement; can efficiently inhibit E. coli, Salmonella, MRSA, C. perfringens and the like; can reduce fecal odor and effectively reduce fecal odor substances in pet excrement, such as indole, cadaverine, spermidine, putrescine and skatole and the like; is safe and harmless, avoids the negative influence of chemical synthetic substances on pet health, prevents clumping, and maximally reduces the influence on cat litter clumping, thereby guaranteeing the use effect.

A method for determining cleavage of a VAMP by a clostridial neurotoxin in a cell that has been contacted with the clostridial neurotoxin under conditions suitable for clostridial neurotoxin activity, the method comprising contacting the cytoplasmic content of the cell with an antibody that binds to a resulting C-terminal product of such cleavage under suitable conditions in vitro or ex vivo and detecting the binding of the antibody to the C-terminal cleavage product. The antibody may, for example, be capable of binding an antigenic polypeptide consisting of 10 to 65 amino acid residues and comprising an epitope comprising an amino acid sequence that is at least 90% identical to an amino acid sequence of at least 8 amino acid residues that is immediately C-terminal to a clostridial neurotoxin cleavage site in the VAMP.

The invention belongs to the technical field of biological enzyme engineering, and particularly relates to a D-psicose 3-epimerase mutant derived from rumen clostridium and application of the D-psicose 3-epimerase mutant. The mutant disclosed by the invention is obtained through specific single-point mutation on the basis of a wild type amino acid sequence of D-psicose 3-epimerase, and specifically, the mutant is obtained through mutation of the following five sites: L159V, Q164E, N238T, E288G and C289I; wherein mutants containing all five single point mutations are named as XT mutants. The mutants significantly improve the thermal stability of the enzyme and the catalytic conversion rate under high substrate concentration, especially under the high substrate concentration of 300-700 g / L, the conversion rate of D-psicose of the XT mutant is improved by 2-3% compared with that of a wild type, and the thermal stability of the XT mutant is improved by 28 times compared with that of the wild type. The mutant is suitable for a high-temperature and high-substrate-concentration industrial conversion system, the production cost of D-psicose can be remarkably reduced, and the mutant has important industrial application value.

The invention discloses a camel source single-domain antibody CB3 for recognizing linear B cell epitope in clostridium difficile methylase CamA and application of the camel source single-domain antibody CB3. The nucleotide sequence of the camel source single-domain antibody CB3 is as shown in SEQ ID NO: 1, and the amino acid sequence of the camel source single-domain antibody CB3 is as shown in SEQ ID NO: 2. The camel source single-domain antibody CB3 disclosed by the invention has the advantages of strong specificity, high sensitivity, good accuracy and the like, and it is proved that the camel source single-domain antibody CB3 can be used for detecting recombinant expressed CD-CamA and endogenous CD-CamA by methods such as enzyme-linked immunosorbent assay (ELISA) and western blot hybridization (WB).

The invention relates to the technical field of biosensing and medical instruments, in particular to an organic electrochemical transistor sensor and a preparation method and application thereof. According to the specific technical scheme, the surface of a grid electrode is sequentially modified with a mercaptoacetic acid self-assembly layer, an anti-clostridium difficile toxin B (TcdB) antibody (such as E3), ethanolamine and bovine serum albumin (BSA), and a biological function interface with high specific recognition and strong non-specific adsorption resistance is constructed. The preparation method is simple and stable. The obtained sensor has extremely high detection sensitivity (fg / mL level), good selectivity and a wide linear range on TcdB, can complete detection within a few minutes, is particularly suitable for rapid and accurate detection of TcdB in a complex biological sample, and has a wide application prospect in the field of bedside diagnosis of clostridium difficile infection.

The application discloses a kind of non-small cell lung cancer prognosis immunity and nutrition state related intestinal microorganism marker and its application, intestinal microorganism marker specifically includes: Eubacterium hallii, Akkermansia, Lachnospira pectinosus, Lachnospira viviparous, Paraclostridium, Haemophilus influenzae.The relative abundance of intestinal flora is used with patient PNI index, and the correlation of the diversity of intestinal flora, intestinal type and specific strain and PNI is established.The relative abundance of 6 specific strains of intestinal flora is used with patient PNI index to construct the evaluation model of nutrition immunity, by using this model, the relative abundance information of 6 specific strains of new individual is input, and the result of nutrition immunity evaluation is output, without invasive examination, can repeatedly detect, and improve the nutrition immunity state of patient by the intervention of specific intestinal flora.This provides a new way for personalized medicine, helps doctor to formulate more accurate treatment strategy.

The invention discloses an RNA methylation detection kit based on a CRISPR / CtCas12a system and a detection method, and belongs to the technical field of gene detection and molecular diagnosis. According to the invention, heat-resistant Cas12a protein derived from clostridium butyricum is utilized, and an ss-ds DNA activator is rationally designed, so that the difference between trans-cleavage activity of CtCas12a activated by methylated RNA and trans-cleavage activity of CtCas12a activated by unmethylated RNA is remarkably amplified; by further combining with a detection probe, high-sensitivity and single-base-resolution quantitative analysis of methylation modification of multiple RNAs such as m6A and m1A is synchronously realized under the condition that nucleic acid amplification is not needed, and an efficient tool is provided for disease marker screening and clinical precise diagnosis and treatment; besides, the method overcomes antibody dependence and amplification deviation, and is suitable for rapid detection of clinical samples and dynamic monitoring of epitranscriptome, so that the method has a better application prospect in RNA methylation detection.

The present application relates to recombinant Clostridium difficile antigens based on a fusion protein that consists of or comprises a first amino acid sequence and a second amino acid sequence, wherein: a) the first amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of residues 1500-1850 of a C. difficile Toxin A sequence or residues 1500-1851 of a C. difficile Toxin B sequence; and b) the second amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of a long repeat unit located within amino acid residues 1851-2710 of a C. difficile Toxin A sequence or within amino acid residues 1852-2366 of a C. difficile Toxin B sequence; though with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2710 of a C. difficile Toxin A and with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2366 of a C. difficile Toxin B. Also provided is the use of said antigens for the prevention / treatment / suppression of Clostridium difficile infection (CDI), together with methods for generating said antigens, methods for generating antibodies that bind to said antigens, and the use of said antibodies for the prevention / treatment / suppression of CDI.

A recombinant antibacterial peptide TrSub, preparation method and application for the recombinant antibacterial peptide TrSub is disclosed, and belongs to the field of genetic engineering and biotechnology. The amino acid sequence of the recombinant antimicrobial peptide TrSub is shown in SEQ ID No. 1. The nucleotide sequence encoding the amino acid shown in SEQ ID NO.1 is shown in SEQ ID NO.2. The disclosure also provides a method for preparing the recombinant antimicrobial peptide TrSub, wherein the recombinant antimicrobial peptide TrSub has an inhibitory effect on Escherichia coli, Salmonella, Staphylococcus aureus and Clostridium perfringens. The disclosure has good thermal stability, acid resistance, pepsin resistance and low hemolytic activity, and is beneficial to the application of the disclosure in the preparation of fee and feed additive.

The present invention relates to pharmaceutical compositions and diagnostic methods for neurodegenerative diseases, particularly Parkinson's disease. The invention includes compositions comprising anti-Clostridium tetani agents such as tetanus vaccines, anti-tetanus immunoglobulins, and antibiotics. Methods for diagnosis and monitoring Parkinson's disease comprising detecting C. tetani-derived nucleic acids, proteins, or analogues thereof, in biological specimens, are further provided.

The present invention relates to a method for purifying at least one enzyme selected from the group consisting of collagenase type I, collagenase type II, neutral protease, and clostripain from a mixture of substances, comprising at least one hydrophobic interaction chromatography as a method step, characterized in that in the hydrophobic interaction chromatography, the stationary phase comprises a material selected from the group consisting of polypropylene glycol and butyl sepharose. The invention further relates to the use of the enzymes thus purified for pharmaceutical, cosmetic, and / or biochemical purposes.

The application provides application of a prasrachta bacterium in preparation of a product against a porcine reproductive and respiratory syndrome virus, and belongs to the technical field of prevention and control of the porcine reproductive and respiratory syndrome virus (PRRSV). The application first proposes that the prasrachta bacterium is used for prevention and control of the PRRSV, the prasrachta bacterium has a persistent and stable disinfection effect on the PRRSV, and the stable PRRSV inactivation effect is maintained within an action time of 24 hours. Moreover, the prasrachta bacterium has a non-cytotoxicity characteristic, while realizing persistent and efficient virus inactivation, damage of a chemical disinfectant to host cells is avoided. In addition, the prasrachta bacterium is used for prevention and control of the PRRSV, is environment-friendly, provides a safer and more persistent biological disinfection scheme for the PRRSV prevention and control, and highlights the application potential of the prasrachta bacterium in breeding environment disinfection.

The present application relates to the technical field of pet feed additives, and discloses a pet coated postbiotic feed additive containing enzymes and a preparation method, the additive comprising core particles formed by mixing postbiotics and complex enzymes coated with a slow-release coating, and an enteric layer coated on the outside of the core particles. The preparation method comprises: preparing the postbiotics and the slow-release coated complex enzymes respectively, mixing the two to form core particles, and then enteric coating the core particles. The present application protects the activity of functional components through a double-coating structure, so that the functional components are released in the intestinal tract and synergize. The additive can effectively improve the digestion of pet protein, regulate the intestinal microenvironment, significantly proliferate beneficial bacteria such as lactobacillus and prasrmanella, and inhibit escherichia coli, thereby reducing soft stool and maintaining the intestinal health of pets.

The present disclosure relates to methods for preparing Clostridium botulinum working cell bank. Further provided herein are methods of producing a composition comprising a 900 kDa BoNT / A complex, said method comprising an acid precipitation step.

The present invention relates to a process of purifying a protein. Specifically, the present invention relates to a process of purification of a polyclonal antibody and / or antibody fragments. The present invention employs an adsorptive separation using anion exchange chromatography and cation exchange chromatography along with ultrafiltration and diafiltration to achieve high-purity antibody / or antibody fragments. The process provided in the present invention is applicable for polyclonal antibody and / or antibody fragments, which are associated with conditions but not limited to snake envenomation, scorpion envenomation, diphtheria infection, tetanus infection, rabies virus infection and gas gangrene infection due to Clostridium species.

This invention relates to the fields of synthetic biology and metabolic engineering, and particularly to a genetically engineered strain producing high levels of D-allulose, its construction method, and its applications. The strain uses *Escherichia coli* as the starting strain and constructs a phosphorylation / epimerization / dephosphorylation synthetic pathway by introducing *AlsE* from *E. coli* and *CtA6PP* from *Clostridium thermocellum*. Competitive metabolic genes *pgm*, *zwf*, *pfkA*, and *rpiB* are knocked out to enhance carbon flux directing. Furthermore, the expression of *AlsE* and *CtA6PP* is precisely regulated at the transcriptional and translational levels through promoter engineering and RBS engineering to obtain the optimal expression combination. The engineered strain achieves a D-allulose yield of 5.26 g / L in in vitro fermentation and 33.05 g / L in a 5L fed-batch fermenter, exhibiting advantages of high yield, stability, and ease of scale-up, making it suitable for industrial production of D-allulose.

Single domain antibodies which bind to Clostridium difficile toxin B and their use in the treatment and prevention of Clostridium difficile infection. Nucleic acids and vectors encoding the single domain antibodies, host cells for expression of the single domain antibodies, methods of manufacture and compositions.

The present invention features thermostable protein binding scaffolds containing framework regions and variable loop regions that can be mutagenized to bind a desired target. The scaffolds are derived from the Carbohydrate Binding Module Family 32 (CBM32) protein domain of Clostridium perfringens hyaluronidase (NagH). The robust framework of the scaffolds described herein allows for the development of custom, high performance affinity chromatography resins compatible with the harsh conditions of process-scale applications that can be adaptable to a wide diversity of target substrates.

The invention discloses an ethanol-producing clostridium engineering strain for producing ethanol and acetic acid as well as a construction method and application of the ethanol-producing clostridium engineering strain, and belongs to the field of synthetic biology and metabolic engineering. Aiming at the technical problems of limited energy metabolism, slow growth and low product yield of the clostridium ethanologenes in the synthesis gas fermentation process, the invention adopts a push-pull-resistance synergistic metabolism reprogramming strategy: firstly, knocking out by-product synthesis genes budA and ldhA to block carbon shunt; then integrating and expressing endogenous transcription factors CLAURS14020 and CLAURS08380, which are subjected to energy stress induction screening, and a pyruvate-phosphate double kinase PPDK coding gene at the knockout site, and dragging a carbon metabolic flux, wherein the endogenous transcription factors CLAURS14020 and CLAURS08380 are subjected to energy stress induction screening; and finally, introducing an energy metabolism enhancement gene Rnf complex to enhance cell energy supply. The engineering strain constructed by the invention can efficiently utilize the synthesis gas as a carbon source, obviously improves the yield of ethanol and acetic acid, and is suitable for green manufacturing of biofuels and chemicals.

A method of producing an alcohol or alcohol precursor from a cellulosic material and a genetically modified live ethanologenic organism, wherein the method comprises the steps of:exposing said genetically modified live ethanologenic organism to a culture media with a pH of between 2 and 9 thereby creating an incubation mixture;exposing said incubation mixture to a source of cellulose;incubating said genetically modified live ethanologenic organism in said incubation mixture with said source of cellulose under aerobic and / or anaerobic conditions at a temperature ranging from 0° C. to 60° C. for a first period of time sufficient for the degradation of cellulose, thereby creating a degraded cellulose mixture;optionally, incubating said genetically modified live ethanologenic organism in said degraded cellulose mixture under aerobic and / or anaerobic conditions at a temperature ranging from 0° C. to 60° C. for a second period of time sufficient for the production of said alcohol or alcohol precursor; andoptionally, recovering said alcohol or alcohol precursor from the cells and / or spent culture media.wherein said genetically modified live ethanologenic organism comprises at least one of the following polynucleotide sequences in its genome:i. at least one endoglucanase (cen-like) polynucleotide sequence selected from the group consisting of an endoglucanase A-like (cenA-like) polynucleotide sequence, an endoglucanase B-like (cenB-like) polynucleotide sequence and an endoglucanase C-like (cenC-like) polynucleotide sequence;ii. an exoglucanase (cex-like) polynucleotide sequence; andiii. a β-glucosidase 1 (bgl1) polynucleotide sequence;wherein said source of cellulose has a lignin content of at most 1 wt. % and a hemicellulose content of at most 15 wt. %, and wherein said live ethanologenic organism belongs to a genus is selected from the group consisting of: Aspergillus, Mucor, Zymomonas, Escherichia, Clostridia, Bacillus, and Pseudomonas.

The present application provides an antibacterial protein targeting Clostridium innocua and a preparation method and application thereof. Specifically, the present application provides an antibacterial protein targeting Clostridium innocua or a chimera thereof, wherein the antibacterial protein comprises one or more of the following proteins formed by the following amino acid sequences: (a) an amino acid sequence shown in any one of SEQ ID NO: 1 to SEQ ID NO: 8; (b) a derived sequence obtained by replacing, adding and / or deleting one or more amino acids from the amino acid sequence of (a) and having the same function as (a); (c) a derived amino acid sequence having an identity of more than 85% or more than 90% with any one of SEQ ID NO: 1 to SEQ ID NO: 8. The antibacterial protein of the present application can efficiently kill Clostridium innocua of different sources, including strains with antibiotic resistance, and has specificity.

To provide a method for evaluating dementia, and a composition for preventing or treating a decline in brain function, or for maintaining or improving brain function. [Solution] The gut microbiota of healthy individuals, individuals with mild cognitive impairment, and individuals with Alzheimer's disease were compared. As a result, microorganisms belonging to the genus Faecalibacterium were selected as gut microbiota associated with cognitive function. Furthermore, it was revealed that Faecalibacterium prausnitzii, which possesses specific DNA, has an improving effect on cognitive decline such as learning and memory impairment.

The application discloses a kind of recombinant prasillum fpPRPS protein, the amino acid sequence of the recombinant protein is as shown in SED ID No.3, the nucleotide sequence of the gene of the recombinant protein is as shown in SED ID No.2.It is proved by experiment that the recombinant prasillum fpPRPS protein prepared by the application has effective anti-inflammatory and antitumor components, and is simple to prepare, good in activity, high in purity, small in toxicity, easy to promote and apply clinically and commercially, and has important significance for effectively treating and relieving intestinal inflammation and the occurrence of various tumors including intestinal tumors and the treatment of various inflammations or tumors related to Th17.